Alamar Biosciences, Inc.

EFFECT effective

Alamar Biosciences, Inc. has received SEC approval for its IPO, with the offering becoming effective on April 20, 2026. The filing confirms the initial public offering of 11,250,000 shares at $17.00 per share, with underwriters including J.P. Morgan, BofA Securities, TD Cowen, Leerink Partners, and Stifel. The company plans to use proceeds for growth initiatives, and its NULISA technology platform focuses on precision proteomics for early disease detection.

424B4 priced

Price $17.00 · 11,250,000 shares · Gross proceeds $191,250,000

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of 11,250,000 shares of common stock at $17.00 per share, with total proceeds of $191.25 million. The company, which focuses on precision proteomics for early disease detection, is listed on Nasdaq under the symbol ALMR. As an emerging growth company, it may utilize reduced reporting requirements post-IPO. The offering includes underwriting discounts and an option for underwriters to purchase additional shares.

EFFECT effective

Alamar Biosciences, Inc. has received effectiveness for its S-1 registration statement, indicating the IPO is proceeding. The previous filing was a CERT, likely a correction or amendment. No detailed operational or financial updates are visible in the provided text.

CERT inactive

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of 9,375,000 shares of common stock, with an expected price range of $15.00 to $17.00 per share. The company, an emerging growth company, focuses on precision proteomics for early disease detection. The offering is contingent on Nasdaq listing approval, and underwriters include J.P. Morgan, BofA Securities, and TD Cowen. The company emphasizes its growth in revenue, customer base, and instrument installed base.

S-1/A amended

Price $16.00 · Range $15.00 to $17.00 · 9,375,000 shares

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of 9,375,000 shares of common stock at an expected price range of $15.00 to $17.00 per share. The offering is contingent on Nasdaq listing approval under the symbol 'ALMR.' The company, an emerging growth company and smaller reporting company, emphasizes its precision proteomics platform for early disease detection. The filing includes underwriting details, risk factors, and financial projections, with proceeds intended for growth initiatives.

8-A12B effective

Alamar Biosciences, Inc. is registering its common stock for listing on The Nasdaq Stock Market LLC under the ticker symbol 'ALMR'. The filing references the previously filed S-1 registration statement (File No. 333-294697), which detailed the company's initial public offering (IPO) of 9,375,000 shares at an expected price range of $15.00-$17.00 per share. The current 8-A12B form confirms the registration of securities under Section 12(b) of the Exchange Act, with no exhibits required due to the nature of the registration.

S-1/A amended

Range $15.00 to $17.00 · 9,375,000 shares

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of 9,375,000 shares of common stock at an expected price range of $15.00 to $17.00 per share. The company, which focuses on precision proteomics for early disease detection, has applied for Nasdaq listing under the symbol 'ALMR.' The offering includes an underwriter option to purchase up to 1,406,250 additional shares. Alamar is an emerging growth company and smaller reporting company, which may allow it to adopt reduced reporting requirements post-IPO.

S-1 filed

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its precision proteomics platform. The company specializes in proprietary NULISA technology for detecting low-abundance protein biomarkers with high sensitivity, targeting applications in research, translational studies, and diagnostics. Revenue grew 195% year-over-year to $74.2M in 2025, though the company has incurred net losses since inception. The IPO is contingent on Nasdaq listing approval, with underwriters including J.P. Morgan and BofA Securities.

DRS/A amended

Alamar Biosciences, Inc. is conducting an initial public offering (IPO) of its common stock, with the offering price expected to range between $X and $Y per share. The company intends to list its shares on a stock exchange under the symbol 'ALMR,' contingent on obtaining listing approval. As an emerging growth company and smaller reporting company, Alamar may utilize reduced reporting requirements post-IPO. The offering includes underwriter options for additional shares and highlights risks associated with its proteomics technology and market acceptance.

DRS/A amended

Alamar Biosciences, Inc. is preparing for its initial public offering (IPO) of common stock, with an expected price range and listing on a stock exchange under the symbol 'ALMR.' The filing amends the S-1 registration statement, emphasizing the company's status as an emerging growth company and smaller reporting company. The offering is contingent on obtaining listing approval, and the company intends to include missing financial information in a future amendment.

DRS filed

Alamar Biosciences, Inc. has submitted a confidential DRS filing for an upcoming initial public offering (IPO) of its common stock. The filing outlines the company's intention to offer shares with an expected price range, contingent on listing approval on a stock exchange under the symbol 'ALMR.' The company qualifies as an emerging growth company and a smaller reporting company, which may impact its future reporting requirements. The registration statement includes a preliminary prospectus with risk factors, underwriting details, and a note regarding the omission of certain financial statements due to regulatory exemptions.